Alan Horsager, Ph.D., President and Chief Executive Officer of Duet, to Present on
TLR9 Activation and STAT3 Inhibition: A Bifunctional Approach to Immuno-Oncology
Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — to Present at the 3rd Annual STING & TLR-Targeting Therapies Summit
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here